Sector revisions Protalix BioTherapeutics, Inc.

Stocks

Delayed NYSE Other stock markets 16:00:00 2026-06-18 EDT			5-day change	1st Jan Change
2.220 ^USD	+9.90%		+8.29%	+23.33%

05-13	Protalix BioTherapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026
05-13	Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	PROTALIX BIOTHERAPEUTICS, INC.							2
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							23
	ABBVIE INC.							29
	ROCHE HOLDING AG							18
	ASTRAZENECA PLC							21
	NOVARTIS AG							21
	NOVO NORDISK A/S							23
	AMGEN INC.							30
	GILEAD SCIENCES, INC.							28
	PFIZER INC.							27
	VERTEX PHARMACEUTICALS INCORPORATED							29
	BRISTOL-MYERS SQUIBB COMPANY							25
	GSK PLC							19
	SANOFI							23
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							16
	BAYER AG							19
	Average							22
	Weighted average by Cap.							25